Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECAP-GLP1: Semaglutide for Prevention of HTG-Induced Acute Pancreatitis Recurrence
NCT07617155Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide in hypertriglyceridemia-induced acute pancreatitis (HTGP), sponsored by Peking Union Medical College Hospital. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
03
Conditions
hypertriglyceridemia-induced acute pancreatitis (HTGP)
Beyond the preview
Go deeper on NCT07617155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07617155.